Cargando…
IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment
Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens and also to autoantigens. We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose‐blott...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950058/ https://www.ncbi.nlm.nih.gov/pubmed/26234649 http://dx.doi.org/10.1111/all.12711 |
_version_ | 1782443520989069312 |
---|---|
author | Lucae, S. Schmid‐Grendelmeier, P. Wüthrich, B. Kraft, D. Valenta, R. Linhart, B. |
author_facet | Lucae, S. Schmid‐Grendelmeier, P. Wüthrich, B. Kraft, D. Valenta, R. Linhart, B. |
author_sort | Lucae, S. |
collection | PubMed |
description | Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens and also to autoantigens. We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose‐blotted human epithelial cell extracts and IgE levels to environmental allergens by quantitative ImmunoCap measurements. Skin inflammation was assessed by SCORAD. During full‐dose treatment, a strong reduction in T‐cell‐mediated skin symptoms was observed which reappeared when CyA treatment was reduced or stopped. The intensity of IgE autoreactivity seemed to follow skin inflammation as it was reduced during full‐dose treatment and increased upon inflammation. Interestingly, IgE levels to exogenous allergens were boosted by allergen exposure, declined thereafter, and seemed to be unaffected by CyA. Our data thus indicate that allergen‐specific IgE production is boosted by allergen contact and cannot be reduced by CyA‐mediated T‐cell suppression. |
format | Online Article Text |
id | pubmed-4950058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49500582016-07-28 IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment Lucae, S. Schmid‐Grendelmeier, P. Wüthrich, B. Kraft, D. Valenta, R. Linhart, B. Allergy Brief Communications Atopic dermatitis (AD) patients mount IgE antibody responses to a variety of environmental allergens and also to autoantigens. We analyzed serum samples from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regarding IgE autoreactivity to nitrocellulose‐blotted human epithelial cell extracts and IgE levels to environmental allergens by quantitative ImmunoCap measurements. Skin inflammation was assessed by SCORAD. During full‐dose treatment, a strong reduction in T‐cell‐mediated skin symptoms was observed which reappeared when CyA treatment was reduced or stopped. The intensity of IgE autoreactivity seemed to follow skin inflammation as it was reduced during full‐dose treatment and increased upon inflammation. Interestingly, IgE levels to exogenous allergens were boosted by allergen exposure, declined thereafter, and seemed to be unaffected by CyA. Our data thus indicate that allergen‐specific IgE production is boosted by allergen contact and cannot be reduced by CyA‐mediated T‐cell suppression. John Wiley and Sons Inc. 2015-09-17 2016-01 /pmc/articles/PMC4950058/ /pubmed/26234649 http://dx.doi.org/10.1111/all.12711 Text en © 2015 The Authors. Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Communications Lucae, S. Schmid‐Grendelmeier, P. Wüthrich, B. Kraft, D. Valenta, R. Linhart, B. IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment |
title | IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment |
title_full | IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment |
title_fullStr | IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment |
title_full_unstemmed | IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment |
title_short | IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment |
title_sort | ige responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine a treatment |
topic | Brief Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950058/ https://www.ncbi.nlm.nih.gov/pubmed/26234649 http://dx.doi.org/10.1111/all.12711 |
work_keys_str_mv | AT lucaes igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment AT schmidgrendelmeierp igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment AT wuthrichb igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment AT kraftd igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment AT valentar igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment AT linhartb igeresponsestoexogenousandendogenousallergensinatopicdermatitispatientsunderlongtermsystemiccyclosporineatreatment |